The estimated Net Worth of Gary S. Gillheeney is at least $9.19 Millón dollars as of 30 June 2022. Mr Gillheeney owns over 505,050 units of Organogenesis stock worth over $2,312,428 and over the last 5 years he sold ORGO stock worth over $5,295,786. In addition, he makes $1,581,903 as Pres y CEO & Director at Organogenesis.
Mr has made over 10 trades of the Organogenesis stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 505,050 units of ORGO stock worth $500,000 on 30 June 2022.
The largest trade he's ever made was exercising 505,050 units of Organogenesis stock on 30 June 2022 worth over $500,000. On average, Mr trades about 142,543 units every 44 days since 2020. As of 30 June 2022 he still owns at least 903,292 units of Organogenesis stock.
You can see the complete history of Mr Gillheeney stock trades at the bottom of the page.
Gary S. Gillheeney Sr. is the Pres, CEO & Director at Organogenesis.
As the Pres y CEO & Director of Organogenesis, the total compensation of Mr Sr at Organogenesis is $1,581,903. There are no executives at Organogenesis getting paid more.
Mr Sr is 66, he's been the Pres y CEO & Director of Organogenesis since . There are 3 older and 14 younger executives at Organogenesis. The oldest executive at Organogenesis Holdings Inc. is Alan Ades, 81, who is the Independent Director.
Gary's mailing address filed with the SEC is C/O ORGANOGENESIS HOLDINGS INC., 85 DAN ROAD, CANTON, MA, 02021.
Over the last 5 years, insiders at Organogenesis have traded over $157,938,506 worth of Organogenesis stock and bought 15,146,267 units worth $65,732,558 . The most active insiders traders include Capital Managing Member Iv,..., Alan A.Erani Albert Erani D... y Glenn H Wisdom Starr Nussdorf. On average, Organogenesis executives and independent directors trade stock every 24 days with the average trade being worth of $1,067,103. The most recent stock trade was executed by Patrick Bilbo on 28 March 2024, trading 152,250 units of ORGO stock currently worth $179,655.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic allograft wound covering and surgical barrier for application in the care of chronic and acute wounds or surgical implantation in spine, orthopedic, and sports medicine applications; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft, a dermal substitute for the treatment of DFUs; NuShield, a dehydrated placental tissue wound covering and surgical barrier applied to the target tissue to support native healing; and PuraPly Antimicrobial, an antimicrobial barrier skin substitute to treat chronic and acute wounds. Its surgical and sports medicine products comprise NuCel, a surgically implanted allograft used primarily in spinal and orthopedic surgical applications; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor, a chorionic membrane wound covering; TransCyte, a bioengineered tissue for the treatment of partial thickness burns; and Gintuit, a bioengineered bi-layered living cellular tissue for the treatment of mucogingival conditions in adults. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Organogenesis executives and other stock owners filed with the SEC include: